2,3-二羟基-6,7-二氯喹喔啉 | 25983-13-5

• 物质功能分类: 医药中间体 - 原料药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2,3-二羟基-6,7-二氯喹喔啉
• 中文别名: 2,3-二氯-4-三氟甲基甲苯；6,7-二氯-1,4-二氢-2,3-喹喔啉二酮；6,7-二氯喹喔啉-2,3(1H,4H)-二酮
• 英文名称: 6,7-dichloro-1,4-dihydroquinoxaline-2,3-dione
• 英文别名: 6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione；6,7-dichloroquinoxaline-2,3-dione；6,7-dichloroquinoxaline-2,3(1H,4H)-dione；DCQX
• CAS: 25983-13-5
• 化学式: C₈H₄Cl₂N₂O₂
• mdl: MFCD00078575
• 分子量: 231.038
• InChiKey: AVBSIKMUAFYZAV-UHFFFAOYSA-N

物化性质

• 熔点：
  170-170.5 °C
• 密度：
  1.590±0.06 g/cm3(Predicted)
• 碰撞截面：
  143 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温下保存于惰性气体中

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione
Synonyms: 6,7-Dichloroquinoxaline-2,3-diol

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6,7-Dichloroquinoxaline-2,3(1H,4H)-dione
CAS number: 25983-13-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H4Cl2N2O2
Molecular weight: 231.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

2,3-二羟基-6,7-二氯喹喔啉可用作医药合成中间体。

制备步骤

在0℃下，将10克（93.5毫摩尔）3,4-二氯苯胺和10.4克（103毫摩尔）三乙胺溶解于100毫升无水二氯甲烷中，然后滴加10克（98毫摩尔）乙酸酐。将混合物在室温下搅拌6小时后，进行浓缩处理。接着，将残余物溶于乙酸乙酯中，并依次用水分和盐水洗涤。干燥后再次浓缩，并通过重结晶进一步纯化。

反应信息

• 作为反应物：
  描述：

  2,3-二羟基-6,7-二氯喹喔啉 在 一氯化碘 作用下， 以 氢氧化钾 、 concentrated H2 SO4 为溶剂， 以75%的产率得到5,8-Diiodo-6,7-dichloro-1,4-dihydro-2,3-quinoxalinedione
  参考文献：
  名称：

  Glycine receptor antagonists and the use thereof

  摘要：

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的副作用，以及治疗焦虑、慢性疼痛、癫痫、诱导麻醉和治疗精神病的方法，通过向需要此类治疗的动物施用一种对甘氨酸结合位点具有高亲和力、无PCP副作用且能穿过动物血脑屏障的化合物来进行披露。还披露了新型的1,4-二氢喹诺酮-2,3-二酮，及其药物组合物。还披露了1,4-二氢喹诺酮-2,3-二酮的高度可溶性铵盐。

  公开号：

  US05514680A1
• 作为产物：
  描述：

  4,5-二氯-2-硝基苯胺 在 palladium-carbon 盐酸 作用下， 以 乙醇 为溶剂， 生成 2,3-二羟基-6,7-二氯喹喔啉
  参考文献：
  名称：

  Glycine receptor antagonists and the use thereof

  摘要：

  治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的副作用，以及治疗焦虑、慢性疼痛、癫痫、诱导麻醉和治疗精神病的方法，通过向需要此类治疗的动物施用一种对甘氨酸结合位点具有高亲和力、无PCP副作用且能穿过动物血脑屏障的化合物来进行披露。还披露了新型的1,4-二氢喹诺酮-2,3-二酮，及其药物组合物。还披露了1,4-二氢喹诺酮-2,3-二酮的高度可溶性铵盐。

  公开号：

  US05514680A1

文献信息

• Synthesis of Novel Halogenated Heterocycles Based on o-Phenylenediamine and Their Interactions with the Catalytic Subunit of Protein Kinase CK2
  作者：Maria Winiewska-Szajewska、Agnieszka Monika Maciejewska、Elżbieta Speina、Jarosław Poznański、Daniel Paprocki

  DOI：10.3390/molecules26113163

  日期：——

  Protein kinase CK2 is a highly pleiotropic protein kinase capable of phosphorylating hundreds of protein substrates. It is involved in numerous cellular functions, including cell viability, apoptosis, cell proliferation and survival, angiogenesis, or ER-stress response. As CK2 activity is found perturbed in many pathological states, including cancers, it becomes an attractive target for the pharma

  蛋白激酶CK2是高度多效性蛋白激酶，能够磷酸化数百种蛋白底物。它涉及许多细胞功能，包括细胞活力，凋亡，细胞增殖和存活，血管生成或ER应激反应。由于发现CK2活性在包括癌症在内的许多病理状态中受到干扰，因此它成为该药的有吸引力的靶标。已经开发了许多低质量的ATP竞争性抑制剂，其中大多数已被卤化。我们测试了六种系列卤代杂环配体的结合，这些配体衍生自可商购的4,5-二卤代苯-1,2-二胺。选择这些配体系列以使支架作用与直接归因于卤素原子存在的疏水相互作用分离。最初使用计算机分子对接技术来测试每种配体在CK2的ATP结合位点结合的能力。将HPLC衍生的配体疏水性数据与通过小体积差示扫描荧光法（nanoDSF）评估的结合亲和力进行比较。我们确定了三个有希望的配体支架，其中两个尚未被描述为CK2抑制剂，但可能导致有效的CK2激酶抑制剂。已经确定了在nanoDSF分析中被鉴定为最有前途的八种化合物对CK
• A new facile, efficient synthesis and structure peculiarity of quinoxaline derivatives with two benzimidazole fragments
  作者：Vakhid A. Mamedov、Nataliya A. Zhukova、Victor V. Syakaev、Aidar T. Gubaidullin、Tat'yana N. Beschastnova、Dil'bar I. Adgamova、Aida I. Samigullina、Shamil K. Latypov

  DOI：10.1016/j.tet.2012.10.045

  日期：2013.1

  A highly efficient and versatile method for the synthesis of quinoxaline derivatives with two benzimidazole fragments have been developed on the basis of the ring contraction of 3-(benzimidazo-2-yl)quinoxalin-2(1H)-one with 1,2-diaminobenzene and its various types of substituted and condensed derivatives. Owing to the inter- and intramolecular processes, involving self association, proton exchange

  基于3-（苯并咪唑-2-基）喹喔啉-2（1 H）-与1,2-的环收缩，已开发出一种高效且通用的具有两个苯并咪唑片段的喹喔啉衍生物的合成方法。二氨基苯及其各种类型的取代和稠合衍生物。由于分子间和分子内过程，涉及桥联和相邻碳原子的大多数双-苯并咪唑基喹喔啉信号的几种形式之间的自缔合，质子交换，构象和/或互变异构交换，且NMR光谱中的苯并咪唑片段变宽。苯并咪唑片段与分子的喹喔啉核心之间的共轭作用比喹喔啉衍生物（10c）与其噻二唑[ f ]-（17）和吡咯并[ a ]-（19）环化了衍生物，导致整个分子的平面度更大。
• HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE
  申请人：Borchardt Allen J.

  公开号：US20100120741A1

  公开（公告）日：2010-05-13

  The present invention relates to compounds and methods which may be useful as inhibitors of H 1 R and/or H 4 R for the treatment or prevention of inflammatory, autoimmune, allergic, and ocular diseases.

  本发明涉及化合物和方法，这些化合物和方法可能用作H1R和/或H4R的抑制剂，用于治疗或预防炎症性、自身免疫性、过敏性和眼部疾病。
• Rationalization of Benzazole-2-carboxylate versus Benzazine-3-one/Benzazine-2,3-dione Selectivity Switch during Cyclocondensation of 2-Aminothiophenols/Phenols/Anilines with 1,2-Biselectrophiles in Aqueous Medium
  作者：Tejas M. Dhameliya、Sumit S. Chourasiya、Eshan Mishra、Pradeep S. Jadhavar、Prasad V. Bharatam、Asit K. Chakraborti

  DOI：10.1021/acs.joc.7b01548

  日期：2017.10.6

  insights of these cyclocondensation reactions using the hard–soft acid–base principle, quantum chemical calculations (density functional theory), and orbital interaction studies rationalize the selectivity switch of benzothiazole-2-carboxylates versus benzazine-3-ones/benzazine-2,3-diones. The presence of water facilitates these cyclocondensation reactions by lowering of the energy barrier.

  的2-氨基苯硫酚与1,2- biselectrophiles如乙醛酸乙酯和草酸二乙酯在水性介质中的引线经由5-形成苯并噻唑-2-羧酸酯的环化缩合反应内切- trig的过程相反Baldwin的规则。另一方面，2-氨基苯酚/苯胺的反应通过6- exo - trig生成了相应的benzazine-3-ones或benzazine-2,3-diones。符合鲍德温规则的流程。使用硬-软酸碱原理，量子化学计算（密度泛函理论）和轨道相互作用研究对这些环缩合反应的机理进行了深入研究，从而使苯并噻唑-2-羧酸酯与苯并三嗪-3-ones / benzazine-2的选择性转换合理化。 ，3-二酮。水的存在通过降低能垒来促进这些环缩合反应。
• 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants
  作者：Reinhard Sarges、Harry R. Howard、Ronald G. Browne、Lorraine A. Lebel、Patricia A. Seymour、B. Kenneth Koe

  DOI：10.1021/jm00170a031

  日期：1990.8

  (trifluoromethyl)[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 28 nM at the A1 receptor. The most potent A2 ligand is 128 (CP-66,713; 4-amino-8-chloro-1- phenyl[1,2,4]triazolo[4,3-a]quinoxaline) with an IC50 of 21 nM at the A2 receptor and a 13-fold selectivity for this receptor. Representatives from this series appear to act as antagonists at both A1 and A2 receptors since they antagonize the

  制备了一系列的4-氨基[1,2,4]三唑并[4,3-a]喹喔啉。此类化合物中的许多化合物在急性给药后可降低大鼠Porsolt行为绝望模型的固定性，因此可能具有作为新型且速效抗抑郁药的治疗潜力。该测试中的最佳活性与1位上的氢，CF3或小烷基，与4位上的小烷基取代的NH2，NH-乙酰基或胺以及氢或8个卤素取代基有关在芳香环上。此外，许多这些4-氨基[1,2,4]三唑并[4,3-a]喹喔啉与腺苷A1和A2受体狂热结合，在某些情况下非常选择性地结合。这些化合物的A1亲和力是通过抑制大鼠大脑皮层膜中tri化的CHA（N6-环己基腺苷）结合而测定的，A2亲和性是通过抑制tri化的NECA（5'-（N-乙基氨基甲酰基）腺苷）与大鼠纹状体匀浆中的结合来测定的。存在冷的N6-环戊基腺苷。结构-活性关系（SAR）研究表明，最佳的A1亲和力与1位的乙基， 或C2F5、4位的NH-iPr或NH-环烷基以及8-